Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 64 of 115 for:    "Viral Infectious Disease" | "Ledipasvir"

Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03261349
Recruitment Status : Not yet recruiting
First Posted : August 25, 2017
Last Update Posted : August 25, 2017
Sponsor:
Information provided by (Responsible Party):
National Taiwan University Hospital

Brief Summary:

We and other investigators have revealed an association between Hepatitis C virus (HCV) seropositivity and an increased risk of developing marginal zone B-cell lymphoma (MZ), lymphoplasmacytic lymphoma (LPL, also known as Waldenström's macroglobulinemia), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL). The sustained virologic response (SVR) to treatment with interferon or pegylated (Peg)IFN with ribavirin was closely associated with the regression of HCV-associated B-cell NHL (mainly MZL, and LPL).

Currently, the second-generation direct-acting antiviral agents (DAAs), such as sofosbuvir, have been shown to have a higher cure rate, less side effects, and a shorter duration of therapy for chronic HCV infection. After the approval of DAA for HCV therapy, several recent anecdotal case reports showed that indolent low-grade B-cell NHLs regressed after HCV clearance by DAAs. It is noted that the time to complete remission of these lymphomas was around 20 to 24 weeks after starting DAAs. These findings indicate that DAAs can eradicate the trigger of lymphomagenesis by curing chronic HCV infection.

Because DAAs are more potent and efficient than pegylated (Peg) interferon plus ribavirin and well-tolerated for the treatment of HCV infection, it is reasonable to use DAAs as the frontline treatment for HCV-positive patients with indolent B-cell NHL, such as MZL, LPL, and low-grade FL, who do not require immediate cytoreductive therapy. The aim of this proposal is to assess whether Harvoni® (ledipasvir and sofosbuvir) could eradicate HCV and lead to durable complete remission of these lymphomas..


Condition or disease Intervention/treatment Phase
Indolent Lymphoma Drug: Ledipasvir and sofosbuvir Phase 2

Detailed Description:

Although several epidemiological studies, including our study have been demonstrated the link between HCV and B-cell non-Hodgkin's lymphoma (NHL), the direct evidence of the HCV-associated-NHL remains uncertain. Direct antiviral agents (DAA) have been shown to have a higher cure rate, less side effects, and a shorter duration of therapy for chronic HCV infection. Whether DAA treatment can cure HCV-associated indolent B-cell NHL remains unclear? If yes, a direct evidence of HCV-associated lymphomagenesis will be approved. Because DAAs are more potent and efficient than pegylated (Peg) interferon plus ribavirin and well-tolerated for the treatment of HCV infection, it is reasonable to use DAAs as the frontline treatment for HCV-positive patients with indolent B-cell NHL, such as MZL, LPL, and low-grade FL, who do not require immediate cytoreductive therapy. The aim of this proposal is to assess whether Harvoni® (ledipasvir and sofosbuvir) could eradicate HCV and lead to durable complete remission of HCV-associated indolent B-cell NHL.

In the translational part, we will assess the expression pattern of BAFF-related canonical and non-canonical NF-κB signaling molecules by immunohistochemical (IHC) staining, and t(11;18)(q21;q21), and t(14;18)(q32;q21) by fluorescence in situ hybridization (FISH) in pre-treatment tumors samples of patients in prospectively predicting the antiviral responsiveness of HCV-positive indolent B-cell NHLs. The serum cytokines and chemokines, IFN-gamma, TNF-alpha, IL-4, IL-5, IL-6, IL-13 and CXCL13, BAFF level, and HCV RNA load before and after DAA treatment in HCV-associated indolent B-cell NHLs will be examined. The genotype of the HLA class II, and cloning followed by sequences of the VH region of the immunoglobulin gene derived from pre-treatment tumor samples will be assessed.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 21 participants
Intervention Model: Single Group Assignment
Intervention Model Description: New Direct-Acting Antiviral Agent, HARVONI® (ledipasvir/sofosbuvir)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Phase II Study of New Direct-Acting Antiviral Agent, HARVONI® (Ledipasvir/Sofosbuvir), for the Treatment of Genotype 1 or 2 HCV-Associated Indolent B-Cell Non- Hodgkin's Lymphoma
Estimated Study Start Date : September 1, 2017
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : August 15, 2021


Arm Intervention/treatment
Experimental: Anti-HCV (Ledipasvir and sofosbuvir)
Harvoni® (90 mg ledipasvir and 400 mg sofosbuvir) one tablet daily for 12 weeks
Drug: Ledipasvir and sofosbuvir
To assess whether Harvoni® (ledipasvir and sofosbuvir) could eradicate HCV and lead to durable complete remission of these lymphomas.
Other Name: HARVONI®




Primary Outcome Measures :
  1. The complete remission rate [ Time Frame: During the first-year, every 3 months to evaluate ]
    The complete remission rate by using Harvoni® (ledipasvir and sofosbuvir) as the first-line line therapy.


Secondary Outcome Measures :
  1. The durability of complete remission (disease-free interval) [ Time Frame: Follow-up every 3 motnhs for 3 years ]
    The lymphoma-free

  2. The overall response rate [ Time Frame: During the first-year, every 3 months to evaluate ]
    Complete remission and partial remission rate

  3. The association between HCV RNA load and response of lymphoma. [ Time Frame: During the first-year, every 3 months to evaluate ]
    The assessment of HCV RNA load

  4. The toxicity of Harvoni®. [ Time Frame: 3 months ]
    The assessment of toxicity during the first 3 months

  5. Potential biomarkers predicting the response of Harvoni®. [ Time Frame: 3 years ]
    Translational study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients older than 18 years with histologically proven diagnoses of indolent B-cell NHLs and with positive genotype 1 or 2 HCV (non-cirrhotic status) were eligible.
  2. Indolent B-cell NHLs includes:

    • Low-grade marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type: known as MALT lymphoma.
    • Splenic marginal zone lymphomas (SMZL)
    • Waldenström's macroglobulinemia (WM, known as lymphoplasmacytic lymphoma) .
    • Grade 1, 2 follicular lymphoma (FL). 3 Stage I to III (modified Ann Arbor stage), and non-life threatening IV lymphoma. 4 Patients had not previously been treated with chemotherapy or immunotherapy, were eligible. 5 Patients with clinical, echographical, or radiological suspicion of lymphoma lesions were eligible.

Exclusion Criteria:

  1. Evidence of histologic transformation to a high-grade lymphoma (such as grade 3 and 4 follicular lymphoma, and high-grade MALT lymphoma).
  2. Life-threatening disseminated lymphoma.
  3. Primary gastric lesions were not eligible.
  4. Prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer.
  5. Evidence of clinically significant cardiac disease, as defined by history of symptomatic ventricular arrhythmias, congestive heart failure or myocardial infarction within 12 months before study entry.
  6. Evidence of symptomatic central nervous system (CNS) disease.
  7. Evidence of active opportunistic infections.
  8. Liver cirrhosis B and C (Child-Pugh score)
  9. Known HIV infection.
  10. Pregnant or lactating status.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03261349


Contacts
Layout table for location contacts
Contact: Sung-Hsin Kuo, M.D.,Ph.D. +886-2323456 ext 67144 shkuo101@ntu.edu.tw

Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Sung-Hsin Kuo, M.D.,Ph.D. Department of Oncology, National Taiwan University Hospital

Layout table for additonal information
Responsible Party: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT03261349     History of Changes
Other Study ID Numbers: 201612066MIPB
First Posted: August 25, 2017    Key Record Dates
Last Update Posted: August 25, 2017
Last Verified: August 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by National Taiwan University Hospital:
Follicular lymphoma
MALT lymphoma
Waldenström's macroglobulinemia
Hepatitis C virus
Additional relevant MeSH terms:
Layout table for MeSH terms
Ledipasvir
Ledipasvir, sofosbuvir drug combination
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antiviral Agents
Sofosbuvir
Anti-Infective Agents